---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-22-000057"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T22:09:24.269532+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q1 2022 revenue $356M, EPS $0.21; cabozantinib franchise $310.3M

## Summary
- Total revenues $356.0M vs $270.2M YoY; net product revenues $310.3M vs $227.2M, driven by higher cabozantinib volume.
- GAAP net income $68.6M ($0.21 diluted EPS) vs $1.6M ($0.00); non-GAAP EPS $0.26 vs $0.09.
- Cabozantinib franchise growth: increased demand for CABOMETYX+OPDIVO in first-line RCC and DTC label expansion.
- Cash and investments $2.0B at March 31, 2022, up from $1.9B at December 31, 2021.
- Pipeline advancing: XL092 phase 3 STELLAR-303 to initiate Q2 2022; phase 1 trials of XL092, XB002, XL102 ongoing.

## SEC filing metadata
- accession: 0000939767-22-000057
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976722000057/0000939767-22-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976722000057/exel-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-22-000057
- JSON: https://secwatch.observer/filing/0000939767-22-000057.json
- Plain text: https://secwatch.observer/filing/0000939767-22-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.